Vosevi (sofosbuvir/velpatasvir/voxilaprevir) — Blue Cross Blue Shield of Montana
Hepatitis C virus (HCV) infection
Preferred products
- Epclusa (sofosbuvir/velpatasvir)
- Harvoni (ledipasvir/sofosbuvir)
- Sovaldi (sofosbuvir)
- Ledipasvir/Sofosbuvir
- Sofosbuvir/Velpatasvir
- Mavyret (glecaprevir/pibrentasvir)
- Zepatier (elbasvir/grazoprevir)
Initial criteria
- Patient has FDA labeled diagnosis consistent with requested agent
- Requested agent is FDA labeled for the patient’s genotype
- Patient age consistent with labeling OR supported off-label age use
- Hepatitis B viral (HBV) screening completed and appropriate monitoring in place
- Patient has no labeled contraindications
- Prescriber is specialist or meets AASLD simplified treatment criteria
- If client has preferred agent(s), step therapy exception criteria met (treatment history, intolerance, contraindication, etc.)
Approval duration
Up to treatment duration per FDA labeling